Table 3.
Relative risk of second primary cancer by type of first primary cancer and follow-up period
| 6 months to 1 year | 1 year to 5 years | 5 years to 10 years | Over 10 years | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First primary cancer | O | E | SIR | 95%CI | O | E | SIR | 95%CI | O | E | SIR | 95%CI | O | E | SIR | 95%CI |
| Oral Cavity & Pharynx | 166 | 51 | 3.28 | (2.75–3.80) | 971 | 274 | 3.54 | (3.31–3.77) | 636 | 200 | 3.18 | (2.93–3.44) | 398 | 154 | 2.59 | (2.33–2.86) |
| Oesophagus | 30 | 17 | 1.78 | (1.06–2.49) | 131 | 52 | 2.51 | (2.06–2.97) | 47 | 24 | 1.97 | (1.35–2.59) | 36 | 13 | 2.82 | (1.79–3.84) |
| Stomach | 46 | 47 | 0.98 | (0.67–1.30) | 205 | 188 | 1.09 | (0.93–1.25) | 163 | 122 | 1.34 | (1.12–1.55) | 157 | 106 | 1.48 | (1.24–1.73) |
| Colorectal | 280 | 260 | 1.08 | (0.95–1.21) | 1671 | 1523 | 1.10 | (1.04–1.15) | 1332 | 1118 | 1.19 | (1.13–1.26) | 1158 | 900 | 1.29 | (1.21–1.36) |
| Liver & Intrahepatic Bile Ducts | 20 | 16 | 1.26 | (0.62–1.89) | 58 | 49 | 1.19 | (0.85–1.52) | 28 | 16 | 1.77 | (1.03–2.52) | 17 | 5 | 3.13 | (1.40–4.87) |
| Pancreas | 18 | 21 | 0.87 | (0.40–1.33) | 45 | 39 | 1.15 | (0.78–1.52) | 16 | 12 | 1.30 | (0.56–2.05) | 13 | 7 | 1.86 | (0.66–3.06) |
| Larynx | 53 | 20 | 2.61 | (1.84–3.37) | 361 | 130 | 2.77 | (2.47–3.06) | 256 | 110 | 2.34 | (2.04–2.63) | 223 | 102 | 2.19 | (1.89–2.50) |
| Lung | 201 | 136 | 1.47 | (1.26–1.69) | 642 | 420 | 1.53 | (1.41–1.65) | 411 | 214 | 1.92 | (1.73–2.11) | 306 | 143 | 2.15 | (1.90–2.40) |
| Skin Melanoma | 113 | 89 | 1.28 | (1.03–1.52) | 709 | 631 | 1.12 | (1.04–1.21) | 687 | 561 | 1.22 | (1.13–1.32) | 767 | 583 | 1.32 | (1.22–1.41) |
| Breast female | 197 | 252 | 0.78 | (0.67–0.90) | 1532 | 1807 | 0.85 | (0.80–0.89) | 1632 | 1617 | 1.01 | (0.96–1.06) | 1784 | 1570 | 1.14 | (1.08–1.19) |
| Cervix Uteri | 16 | 12 | 1.31 | (0.56–2.06) | 108 | 75 | 1.45 | (1.16–1.74) | 124 | 73 | 1.69 | (1.38–2.01) | 210 | 125 | 1.68 | (1.44–1.92) |
| Corpus Uteri & NOS | 46 | 49 | 0.95 | (0.65–1.25) | 386 | 335 | 1.15 | (1.03–1.27) | 359 | 320 | 1.12 | (1.00–1.24) | 530 | 386 | 1.37 | (1.25–1.49) |
| Ovary | 20 | 23 | 0.86 | (0.43–1.30) | 105 | 113 | 0.93 | (0.74–1.12) | 102 | 75 | 1.36 | (1.08–1.65) | 140 | 80 | 1.75 | (1.44–2.05) |
| Prostate | 348 | 509 | 0.68 | (0.61–0.76) | 2423 | 3409 | 0.71 | (0.68–0.74) | 1868 | 2461 | 0.76 | (0.72–0.79) | 999 | 1098 | 0.91 | (0.85–0.97) |
| Testis | 7 | 5 | 1.55 | (0.10–3.00) | 63 | 39 | 1.60 | (1.17–2.03) | 70 | 53 | 1.33 | (0.99–1.67) | 207 | 152 | 1.36 | (1.17–1.56) |
| Kidney | 65 | 40 | 1.64 | (1.21–2.07) | 318 | 251 | 1.27 | (1.12–1.41) | 243 | 198 | 1.23 | (1.07–1.39) | 240 | 164 | 1.47 | (1.27–1.66) |
| Bladder | 150 | 85 | 1.77 | (1.47–2.06) | 679 | 476 | 1.43 | (1.32–1.54) | 483 | 338 | 1.43 | (1.30–1.56) | 431 | 266 | 1.62 | (1.46–1.78) |
| Brain & Central Nerves | 15 | 10 | 1.52 | (0.62–2.43) | 38 | 30 | 1.27 | (0.82–1.72) | 25 | 20 | 1.26 | (0.70–1.82) | 35 | 19 | 1.83 | (1.15–2.50) |
| Thyroid | 20 | 14 | 1.46 | (0.73–2.20) | 151 | 103 | 1.46 | (1.22–1.71) | 125 | 104 | 1.20 | (0.98–1.42) | 205 | 131 | 1.57 | (1.34–1.80) |
| Hodgkin Lymphoma | 8 | 5 | 1.53 | (0.21–2.85) | 99 | 34 | 2.89 | (2.28–3.49) | 70 | 33 | 2.09 | (1.56–2.62) | 146 | 52 | 2.78 | (2.30–3.26) |
| Non Hodgkin Lymphoma | 81 | 64 | 1.26 | (0.97–1.56) | 494 | 388 | 1.27 | (1.16–1.39) | 401 | 286 | 1.40 | (1.26–1.54) | 347 | 215 | 1.62 | (1.44–1.79) |
| Multiple Myeloma | 21 | 28 | 0.75 | (0.38–1.12) | 145 | 140 | 1.04 | (0.86–1.21) | 91 | 63 | 1.44 | (1.13–1.76) | 36 | 26 | 1.38 | (0.88–1.88) |
| Leukaemia | 51 | 45 | 1.14 | (0.80–1.48) | 971 | 266 | 1.43 | (1.29–1.58) | 308 | 183 | 1.68 | (1.49–1.88) | 218 | 119 | 1.83 | (1.57–2.08) |
| All Cancers | 2098 | 1901 | 1.10 | (1.06–1.15) | 12,532 | 11,297 | 1.11 | (1.09–1.13) | 10,011 | 8556 | 1.17 | (1.15–1.19) | 9152 | 6706 | 1.36 | (1.34–1.39) |
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals